Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company focused on developing transformative therapies based on its proprietary CRISPR technology. The company’s platform is built around novel CRISPR-Cas enzymes and delivery systems designed to enable precise gene editing in both cell‐based and in vivo applications. Caribou’s core therapeutic areas include oncology, immunology and rare genetic diseases, where its technologies aim to create next-generation cell therapies and targeted gene-editing treatments.
Among Caribou’s leading programs is its allogeneic cell therapy platform, which employs engineered T cells to target blood cancers and solid tumors. The company has also advanced multiple in vivo gene-editing candidates, leveraging lipid nanoparticle and viral delivery technologies to correct disease-causing mutations directly within patients. In addition to therapeutic development, Caribou provides its CRISPR tools and enzyme variants to a broad network of academic and industry collaborators working in human health research, agricultural biotechnology and synthetic biology.
Founded in 2011, Caribou Biosciences traces its origins to the University of California, Berkeley, where Nobel laureate Jennifer Doudna and her colleagues pioneered CRISPR research. Since its inception, the company has grown from an academic spin-out into a publicly traded entity, establishing state-of-the-art research facilities in the San Francisco Bay Area and collaborating with partners worldwide. Caribou’s strategic alliances encompass pharmaceutical collaborations, licensing agreements and joint development projects across North America, Europe and Asia.
Leadership at Caribou includes a seasoned management team with deep expertise in biotechnology, drug development and regulatory affairs. Co-founder and chief scientific officer Jennifer Doudna continues to guide the company’s scientific direction, while the executive team brings experience from leading global biopharma organizations. Together, they oversee a multidisciplinary workforce committed to advancing Caribou’s pipeline of CRISPR-based therapies and expanding the capabilities of gene-editing platforms on a global scale.
